Podiatrist Loses DEA Registration Over State License Issue
Published Date: 6/24/2026
Notice
Summary
Irina Gross, a podiatrist from Ohio, lost her DEA registration because she no longer has the state permission to handle controlled substances. She didn’t ask for a hearing, so the DEA canceled her registration by default. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately, impacting her medical practice and patients.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Named Podiatrist
The Drug Enforcement Administration revoked DEA Certificate of Registration No. FG2593487 issued to Irina Gross, D.P.M., because she no longer has state authority to handle controlled substances. The revocation is effective July 24, 2026; her Ohio DPM and RCP licenses were suspended effective June 11, 2025 and are recorded as permanently revoked in Ohio online records.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-12649, Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee
The Department of Defense is holding a public meeting on June 22, 2026, to discuss updates to the Uniform Formulary, which affects military health beneficiaries and their medication options. This meeting will review recommendations that could change which medicines are covered, potentially impacting costs and access. Anyone interested can join by phone and share their thoughts, making it a great chance to have a say in military healthcare decisions.
Next: 2026-12651, Certain Frozen Fish Fillets From Vietnam; Determination
The U.S. International Trade Commission decided to keep the extra taxes on frozen fish fillets from Vietnam because removing them could hurt American fish businesses. This means importers will still pay these duties, helping protect U.S. jobs and companies. The decision was finalized in June 2026 and affects anyone buying or selling these fish fillets in the U.S.